Neurogenesis, Inc - NEUN

0.0080
USD +0.0080 (0.0000%)
Trade

Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm’d, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm’d Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm’d/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. was founded in 1984 and is headquartered in League City, Texas.

Trade Neurogenesis, Inc at these brokers
1 2 3 4 5 6 7 8 9 10
3.75
  • Platforms: Andriod App, iOS App, Mobile App, WebTrader
  • License: Not Applicable
Your capital is at risk
1 2 3 4 5 6 7 8 9 10
3.75
  • Platforms: Andriod App, Apple App, iOS App, MetaTrader 4, MetaTrader 5, Mobile App, Proprietary, WebTrader
  • License: CySEC, FCA UK
Your capital is at risk
1 2 3 4 5 6 7 8 9 10
4.5
  • Platforms: Andriod App, Apple App, iOS App, Mobile App, WebTrader
  • License: ASIC, CySEC, FCA UK
Your capital is at risk